Research location
Rennes
Ille-et-Vilaine, France
Advertisement
Research activity in Rennes
Ille-et-Vilaine, FranceCureCurrent currently publishes aggregate city-level research activity for this location: 30 trials and 30 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Rennes
25 linked trials · page 1 of 1A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02 · 1 site observation
RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 1 site observation
RECRUITING
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung CancerNCT06868485 · 2025-08-18 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)NCT06976203 · 2025-07-21 · 1 site observation
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation
RECRUITING
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionNCT06736574 · 2024-12-19 · 1 site observation
RECRUITING
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorNCT06472245 · 2024-12-03 · 1 site observation
RECRUITING
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07 · 1 site observation
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31 · 1 site observation
RECRUITING
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority StudyNCT05692999 · 2023-03-20 · 1 site observation
RECRUITING
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.NCT06046131 · 2023-02-28 · 1 site observation
RECRUITING
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionNCT07128199 · 2025-12-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life SettingNCT06639620 · 2024-11-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)NCT04945460 · 2021-12-29 · 1 site observation
COMPLETED
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).NCT05116189 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple SclerosisNCT04777539 · 2021-06-14 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)NCT04191096 · 2020-02-12 · 1 site observation
TERMINATED
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)NCT04003636 · 2019-09-24 · 1 site observation
COMPLETED
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)NCT03631784 · 2018-10-19 · 1 site observation
COMPLETED
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)NCT03553836 · 2018-09-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)NCT03221426 · 2017-10-09 · 1 site observation
COMPLETED
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerNCT03155997 · 2017-07-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)NCT02539810 · 2015-09-01 · 1 site observation
TERMINATED
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.NCT02153645 · 2014-08-18 · 1 site observation
TERMINATED
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple SclerosisNCT01480076 · 2012-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.